Pharming Group (NASDAQ:PHAR) Shares Up 5.8% – Still a Buy?

Pharming Group (NASDAQ:PHAR) shares rose 5.8% on Wednesday . The company traded as high as $7.95 and last traded at $7.88. Approximately 3,625 shares were traded during mid-day trading, a decline of 28% from the average daily volume of 5,057 shares. The stock had previously closed at $7.45.

Wall Street Analyst Weigh In

A number of analysts have commented on PHAR shares. HC Wainwright reaffirmed a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a research note on Thursday, October 24th. Oppenheimer decreased their price objective on shares of Pharming Group from $31.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, October 28th.

Pharming Group Trading Up 1.7 %

The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41. The firm has a 50-day moving average of $8.25 and a two-hundred day moving average of $8.24.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC raised its stake in Pharming Group (NASDAQ:PHAR) by 75.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 41,110 shares of the company’s stock after buying an additional 17,675 shares during the quarter. Silverberg Bernstein Capital Management LLC owned 0.06% of Pharming Group worth $339,000 at the end of the most recent reporting period. 0.03% of the stock is currently owned by institutional investors and hedge funds.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.